Vertebroplasty and Kyphoplasty Market Size & Share, By Product Type (Minimally Invasive, Open Surgery); By End User; Indication; Material; Product - Global Supply & Demand Analysis, Growth Forecasts, Statistical Report 2025-2037

Vertebroplasty and Kyphoplasty Sector: Growth Drivers and Challenges

Growth Drivers

• Reduction in healthcare expenditure: This is one of the most effective growth drivers for the vertebroplasty and kyphoplasty market, which is possible through intervention at the earliest possible stage. As per a clinical study published by AHRQ in 2022, it was demonstrated that early vertebroplasty intervention tends to reduce hospital admissions by almost 33%, leading to USD 1.3 billion in savings for the U.S. health system for approximately two years. Therefore, the study was also successful in identifying a short-term recovery timeline of 14.5 to 3.3 days in comparison to conservative management, thus driving the market growth.

• Presence of administrative reimbursement strategies: This is yet another driver that is continuously uplifting the market across every nation. For instance, in 2023, the Medicare expenditure on kyphoplasty and vertebroplasty achieved the USD 890.7 million mark, which accounted for 143,455 per procedures in 2024. Besides, domestic discrepancies-based reimbursement is 22.3% higher in urban areas when compared to rural areas. But, with the implementation of the Hospital Outpatient Prospective Payment System final rule, there has been expansion in ACS coverage, eventually enhance the procedural volumes by 9% to 13% yearly till 2027.

Historical Patient Growth Shaping the Market

The international vertebroplasty and kyphoplasty market has been undergoing modifications in terms of enlarged recompensating policies, enhanced diagnostic capabilities, and a rising aging population, all of which are reshaped by sustained patient growth. Besides, the Europe and the U.S. markets have flourished rapidly in the last ten years, with an increase in volume by 6% to 8% every year, while developing countries observed double growth owing to health awareness and accessibility. The Medicare policy in the U.S. has focused more on spinal interventions, thus initiating a 40.5% contribution for kyphoplasty procedures and amplifying the market development effectively.

2014-2024 Historical Patient Growth Data

Key Feasible Models for the Vertebroplasty and Kyphoplasty Market Expansion

The future of the market highly depends on country-specific extension models in alignment with reimbursement strategies, cost sensitivity, and health and medical infrastructure. For instance, partnerships formed between government insurance schemes and local hospital centers in China and India have generated an increase in the revenue structure by 13% to 16%, which has been possible by diminishing procedural expenses. Meanwhile, the implementation of value-based procurement methods in Japan and Germany demonstrated in 01-day patient outcomes. Besides, the ASC-compatible device sales have shifted by 18.5% owing to the U.S. outpatient alteration.

Key Feasibility Models for Market Expansion
 

Challenges

• Price control by governments: This constitutes a strict action, which causes a hindrance in the uplifting the vertebroplasty and kyphoplasty market globally. For instance, the stringent and complicated pricing strategies in Europe effectively cap kyphoplasty repayment at €2,200-€2,850 per procedure, which in turn, compels manufacturers to continue with their operation at 31% to 41% low margins. Also, Medtronic partnered with TK Health Insurance and displayed a 28.7% low cost for five years in comparison to conservative management and secured 93% coverage for regional patients.

• Barriers in Medicaid coverage: This is another factor that negatively impacts the market across different regions. According to an article published by CMS in 2023, only 43.5% of overall Medicaid programs take into consideration vertebroplasty as a first-line treatment option. This eventually results in combating 1.2 million low-income VCF patients without any form of accessibility. Besides this, Stryker Corporation addressed this challenge through its Fracture Prevention Partnership program. The aim was to offer bundled payment at 22.8% below the provided commercial rates, which enhanced Medicaid acceptances by 17.5% in 2023.